Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide and Irinotecan in Glioblastoma Multiforme
NCT00039468Phase 2Completed
- Sponsor
- Dartmouth Health
- Start
- Mar 2002
- Primary completion
- Sep 2007
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of thalidomide, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in glioblastoma multiforme (GBM), sponsored by Dartmouth Health. Started Mar 2002; status: completed.
02
Drugs
thalidomideirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00039468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00039468.